Found: 12
Select item for more details and to access through your institution.
DTG/3TC Sabit Doz Kombinasyonu (SDK), TAF Bazlı Rejim (TBR) ile Eş Etkilidir: 96-hafta TANGO Alt-grup Analizleri.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2021, p. 93
- By:
- Publication type:
- Article
2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S67, doi. 10.1093/ofid/ofz359.147
- By:
- Publication type:
- Article
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2011, v. 3, p. 1, doi. 10.2147/HIV.S13902
- By:
- Publication type:
- Article
Pharmacokinetics of Oral and Transdermal Triprolidine.
- Published in:
- 1990
- By:
- Publication type:
- Other
NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LAMIVUDIDINA (3 TC) VERSUS DTG MAIS DOSE FIXA COMBINADA DE TENOFOVIR/EMTRICITABINA (TDF/FTC) EM ADULTOS VIRGENS DE TRATAMENTO ANTIRRETROVIRAL QUE VIVEM COM HIV-1: RESULTADOS DE 48 SEMANAS DOS ESTU.
- Published in:
- Brazilian Journal of Infectious Diseases, 2018, v. 22, p. 56, doi. 10.1016/j.bjid.2018.10.106
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- BMC Infectious Diseases, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2334-13-269
- By:
- Publication type:
- Article
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
- Published in:
- BMC Infectious Diseases, 2003, v. 3, n. 1, p. 10
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 8, p. 1920, doi. 10.1093/cid/ciz1243
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 6, p. 975, doi. 10.1093/cid/ciac036
- By:
- Publication type:
- Article
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1.
- Published in:
- Annals of Internal Medicine, 2011, v. 154, n. 7, p. 445, doi. 10.7326/0003-4819-154-7-201104050-00316
- By:
- Publication type:
- Article
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
- Published in:
- AIDS Research & Therapy, 2008, v. 5, p. 1, doi. 10.1186/1742-6405-5-5
- By:
- Publication type:
- Article